Last updated: March 3, 2026
What is the Drug Identified by NDC 72603-0148?
The National Drug Code (NDC) 72603-0148 corresponds to Rilzabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor developed by Sanofi. It is under development for autoimmune and hematologic indications, notably immune thrombocytopenia (ITP).
Market Overview
Indications and Therapeutic Landscape
- Primary indication: Immune thrombocytopenia (ITP)
- Market size: Estimated at $600 million globally (2022), driven by autoimmune disorder prevalence
- Key competitors:
- Fostamatinib (Tavalisse)
- Romiplostim (Nplate)
- Eltrombopag (Promacta)
- Second-generation BTK inhibitors in autoimmune development
Clinical Progress and Regulatory Status
- Phase 2 trials indicate positive efficacy signals in ITP
- Pending Phase 3 trial initiation
- No FDA approval as of Q1 2023
- Potential for accelerated approval if Phase 3 results are favorable
Market Drivers
- Growing prevalence of autoimmune diseases
- Limitations of current therapies, including side effect profiles and response rates
- No currently approved BTK inhibitors explicitly for ITP, providing a competitive entry point
Pricing and Cost Considerations
Benchmark Prices for Similar Drugs
| Drug |
Approximate Annual Cost |
Indication |
Approval Status |
| Fostamatinib (Tavalisse) |
$75,000 |
ITP |
Approved |
| Romiplostim (Nplate) |
$150,000 |
ITP |
Approved |
| Eltrombopag (Promacta) |
$180,000 |
ITP |
Approved |
Projected Pricing for Rilzabrutinib
- Likely to be priced within the range of existing ITP therapies, adjusted for efficacy and safety profile.
- Forecasted initial annual price: $70,000–$120,000 per patient
- Pricing will depend on trial success, regulatory status, and payer negotiations
Market Penetration and Revenue Projections
Assumptions
- Launch Year: 2024 (tentative, contingent on Phase 3 outcomes)
- Market share: 10-20% within five years post-launch
- Patient population: Estimated at 50,000 eligible patients globally annually
- Average annual treatment cost: $100,000
Revenue Estimates
| Scenario |
Market Penetration |
Annual Revenue |
Notes |
| Conservative |
10% of target market |
$250 million |
Early adoption in the US and Europe |
| Moderate |
15% |
$375 million |
Expanded access through payers |
| Optimistic |
20% |
$500 million |
Global adoption with expanded indications |
Competitive Risks
- Competitors launching similar BTK inhibitors or alternative therapies
- Delays in trial or regulatory approval
- Pricing negotiations limiting gross margins
Price Projection Outlook (2023–2028)
| Year |
Estimated Price Range |
Expected Revenue |
Key Factors |
| 2023 |
N/A (pre-launch) |
$0 |
Data readouts, trial results |
| 2024 |
$70,000–$120,000 |
$0–$300 million |
Approval, initial sales |
| 2025 |
$70,000–$100,000 |
$150–$400 million |
Market expansion, payer access |
| 2026 |
$70,000–$100,000 |
$200–$500 million |
Established presence, pricing stabilization |
| 2027 |
$70,000–$100,000 |
$250–$600 million |
Potential for label expansion |
Policy and Reimbursement Environment
- Reimbursement is likely to follow existing ITP therapy patterns.
- Pricing negotiations with Medicare, Medicaid, and private payers will influence final net prices.
- Fast-track or breakthrough therapy designation could accelerate reimbursement processes.
Key Takeaways
- Rilzabrutinib (NDC 72603-0148) is poised to enter a competitive ITP treatment market contingent on successful Phase 3 data.
- Pricing is projected within existing BTK inhibitor range, approximately $70,000–$120,000 annually.
- Revenue potential could reach mid- to high hundreds of millions annually, depending on market access and regulatory timelines.
- Competitive risks include potential delays, market adoption barriers, and payer pricing negotiations.
- Accelerated approval pathways may influence launch timing and initial pricing strategies.
FAQs
What is the primary market for Rilzabrutinib?
Autoimmune indications, especially immune thrombocytopenia (ITP).
What are the main competitors for this drug?
Fostamatinib, romiplostim, eltrombopag, and other emerging BTK inhibitors.
How does the pricing of Rilzabrutinib compare to existing ITP therapies?
It will likely be priced within the existing range of $70,000–$180,000 annually, with initial estimates around $70,000–$120,000.
When is commercialization expected?
Potential launch in 2024, pending Phase 3 trial success and regulatory approval.
What are the key factors influencing its market success?
Efficacy and safety profile from clinical trials, regulatory decisions, payer acceptance, and market competition.
References
- Medical Economics. (2022). Cost analysis of immune thrombocytopenia treatments.
- IQVIA. (2022). Global immunology market report.
- FDA. (2023). FDA drug approval processes and pathways.
- EvaluatePharma. (2022). Forecast: Hematology drugs market.
- ClinicalTrials.gov. (2023). Rilzabrutinib clinical trial data [online].
Note: Data projections and analysis are based on the latest available information and anticipated clinical development pathways. Actual market performance may differ due to regulatory, clinical, and commercial factors.
